Tests BI 3804379 Doses in Healthy People and Liver Fibrosis Patients
Tests safety of BI 3804379 injections in healthy adults and adults with MASH liver disease.
Plain-language title generated from the registry record
Registry title: A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Key facts
- Where
- Edegem, BelgiumSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06575400, who can take part
Where in Belgium
- SGS Life Science Services - Clinical ResearchEdegem, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boehringer Ingelheim
- Trial code
- NCT06575400
- Record updated
- 7 July 2026
- Original description
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following administration of single rising doses and administration of multiple rising doses.Read full original descriptionShow less
A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Subcutaneous Doses of BI 3804379 in Healthy Male and Female Participants and in Stable Patients With Advanced Fibrosis Due to MASH
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following administration of single rising doses and administration of multiple rising doses.
Inclusion: Healthy male or female (of non-child-bearing potential) participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), respiratory rate (RR), temperature (TEMP)), 12-lead electrocardiogram (ECG), and clinical laboratory tests; Age of 18 to 65 years (inclusive); Body mass index (BMI) of 18.5 to 30.0 kg/m2 (inclusive); Signed and dated written informed consent in accordance with ICH Harmonized Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial Further inclusion criteria apply; Male or female patients with advanced liver fibrosis due to MASH, aged between 18 and 70 years (inclusive) Further inclusion criteria apply.
Exclusion: Relevant surgery after diagnosis or planned during the study period; Participation in another clinical trial or exposure to an investigational drug within 60 days prior to study treatment; Further exclusion criteria apply; Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders that the investigator considers to be of clinical relevance; Further exclusion criteria apply; Evidence of clinically significant or unstable disease increasing risk to the participant; Uncontrolled hypertension or significant cardiovascular disease (e.g., recent myocardial infarction, stroke, or heart failure New York Heart Association (NYHA) class III/IV); Any laboratory value outside the reference range that the investigator considers to be of clinical relevance; Type 1 diabetes or uncontrolled type 2 diabetes (e.g., hemoglobin A1C (HbA1c) ≥10%, recent major treatment changes, or severe hypoglycemia); Severe renal impairment (estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²); Clinically relevant ECG abnormalities, including QT interval corrected for heart rate (QTc) prolongation or risk factors for Torsade de Pointes; Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator; Repeated measurement of systolic BP outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic BP outside the range of 45 to 90 mmHg, or PR outside the range of 45 to 100 beats per minute (bpm); Significant weight loss (≥10%) between diagnosis and screening.